Condition: Renal Cancer · Kidney Cancer · Renal Cell Carcinoma · Sponsor: University of Colorado, Denver
The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.
This description comes directly from the study's public registry record.
Matthew Lee · 720-848-0630 · matthew.lee@cuanscutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Hilands Ranch Hospital | Highlands Ranch, Colorado, United States | Recruiting |
| Lone Tree Medical Center | Lone Tree, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05969496